Skip to content
Oncology Research Hub

New Haven, Connecticut

Cancer clinical trials in New Haven, CT

183 cancer studies are recruiting participants at sites in New Haven as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

New Haven at a glance

  • 183 studies are recruiting at a site in New Haven.
  • By phase: Phase 1 (39), Phase 1/2 (34), Phase 2 (38), Phase 2/3 (3), Phase 3 (46), Phase 4 (1), No phase (9), Observational (13). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (102), university, hospital or other (71), government (10).
  • By research area: Breast Cancer (65), Lung Cancer (47), Lymphoma (37), Prostate Cancer (18), Pancreatic Cancer (10), Melanoma (6).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in New Haven

Basic details from each study's public record (the 30 most recently updated of 183). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Yale University School of Medicine
    Registry record
    NCT06324357 · updated
  2. Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    EMD Serono Research & Development Institute, Inc.
    Study site
    Yale University - Yale University School of Medicine
    Registry record
    NCT07360314 · updated
  3. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT06058377 · updated
  4. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    Yale Comprehensive Cancer Center
    Registry record
    NCT06638307 · updated
  5. An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    Yale Cancer Center
    Registry record
    NCT07222267 · updated
  6. Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    Smilow Cancer Hospital - Yale New Haven Health · Smilow Cancer Hospital Phase 1 Unit · Yale University - Smilow Cancer Hospital; C/O Thomas Ferencz, RPh, BCOP
    Registry record
    NCT04557449 · updated
  7. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Yale Cancer Center
    Registry record
    NCT07503808 · updated
  8. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Smilow Cancer Center/Yale-New Haven Hospital · Yale University
    Registry record
    NCT03723928 · updated
  9. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    ORIC Pharmaceuticals
    Study site
    Yale Cancer Center
    Registry record
    NCT05315700 · updated
  10. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Yale Cancer Center ( Site 0053)
    Registry record
    NCT06393374 · updated
  11. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Relay Therapeutics, Inc.
    Study site
    Yale-New Haven Hospital-Yale Cancer Center
    Registry record
    NCT06982521 · updated
  12. A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    NiKang Therapeutics, Inc.
    Study site
    Yale Cancer Center
    Registry record
    NCT07029399 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in New Haven, CT on ClinicalTrials.gov.

Lung cancer studies recruiting in New Haven

  1. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT06287775 · updated
  2. A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Smilow Cancer Center at Yale-New Haven ( Site 3253)
    Registry record
    NCT07513376 · updated
  3. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Yale University
    Registry record
    NCT07111520 · updated
  4. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT04267848 · updated
  5. Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study site
    Yale Cancer Center
    Registry record
    NCT07080242 · updated
  6. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Yale University School of Medicine ( Site 0201)
    Registry record
    NCT06623422 · updated
  7. A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Yale Cancer Center
    Registry record
    NCT05789082 · updated
  8. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    Smilow Cancer Hospital - Yale New Haven Health · Smilow Cancer Hospital Phase 1 Unit · Yale - New Haven Hospital - Yale Cancer Center
    Registry record
    NCT07090499 · updated
  9. Phase 1 Study of PF-08046033 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    Smilow Cancer Hospital - Yale New Haven Health · Smilow Cancer Hospital Phase 1 Unit · Yale - New Haven Hospital - Yale Cancer Center
    Registry record
    NCT07519655 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in New Haven, CT on ClinicalTrials.gov.

Prostate cancer studies recruiting in New Haven

  1. Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Yale-New Haven Hospital-Yale Cancer Center ( Site 0064)
    Registry record
    NCT06136624 · updated
  2. A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    Genentech, Inc.
    Study site
    Yale Cancer Center
    Registry record
    NCT07567846 · updated
  3. A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Yale University Hospital
    Registry record
    NCT03972657 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in New Haven, CT on ClinicalTrials.gov.

Melanoma studies recruiting in New Haven

  1. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Yale Cancer Center
    Registry record
    NCT06246916 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in New Haven, CT on ClinicalTrials.gov.

Lymphoma studies recruiting in New Haven

  1. Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT05272384 · updated
  2. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT05675410 · updated
  3. Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT06649812 · updated
  4. A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Yale Cancer Center
    Registry record
    NCT06084936 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in New Haven, CT on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in New Haven

  1. Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Yale University
    Registry record
    NCT07621718 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in New Haven, CT on ClinicalTrials.gov.

Ask about studies near New Haven

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call